Top Story

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

06-Jan-2025

|

By Jonathan Smith

Editor's Choice

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

07-Jan-2025

|

By Clara Rodriguez Fernandez

Headlines

Gilead recruits Terray in AI-driven drug discovery pact

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

AbbVie acquires Roche immune drug spinout in $200 million deal

Nintx bags $10 million to fuel develop plant-based therapies from...

Noema Pharma raises $147 million to develop drugs for neurological...

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3...

→

In focus

Top 5 radiopharmaceuticals startups with VC backing

05-Dec-2024 By Clara Rodriguez Fernandez

Insights into creating an inhaler product through jet milling

Paid for and in partnership with Lonza Small Molecules

Psychedelic drug investments surge in 2024: Key startups raising funds and closing deals

16-Jul-2024 By Clara Rodriguez Fernandez

Achieving data integrity: Best practices for secure and reliable data management

Paid for and content provided by METTLER TOLEDO

Featured

Insight

FDA grants orphan drug designation to CervoMed’s dementia drug

FDA grants orphan drug designation to CervoMed’s dementia drug

Clinical trials & development

→

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

07-Jan-2025

By Clara Rodriguez Fernandez

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

19-Dec-2024

By Clara Rodriguez Fernandez

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results

10-Dec-2024

By Larissa Warneck-Silvestrin

Partner insightMore →

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd.

Accurate determination of resin substitution in solid phase peptide synthesis

Content provided by Almac Group

Reliability, scale, and security of supply

Content provided by Univar Solutions USA

Markets & regulatory news

→

Gilead recruits Terray in AI-driven drug discovery pact

Gilead recruits Terray in AI-driven drug discovery pact

19-Dec-2024

By Jonathan Smith

AbbVie acquires Roche immune drug spinout in $200 million deal

AbbVie acquires Roche immune drug spinout in $200 million deal

17-Dec-2024

By Clara Rodriguez Fernandez

Adragos Pharma snaps up Baccinex to expand CDMO network

Adragos Pharma snaps up Baccinex to expand CDMO network

26-Nov-2024

Genesis Therapeutics partners with NVIDIA to boost AI-driven drug discovery

Genesis Therapeutics partners with NVIDIA to boost AI-driven drug discovery

15-Nov-2024

By Liza Laws

Drug delivery & innovation

→

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

06-Jan-2025

By Jonathan Smith

Eli Lilly invests $3bn in injectable drug manufacturing facility

Eli Lilly invests $3bn in injectable drug manufacturing facility

10-Dec-2024

By Clara Rodriguez Fernandez

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

22-Nov-2024

Overcoming nonspecific binding challenges in pharmacokinetic assays

Overcoming nonspecific binding challenges in pharmacokinetic assays

14-Nov-2024

By Liza Laws

Expand your knowledge

Industry Newsletters

Choose from regular, topic-based and special edition briefings

Resource centre

Discover cutting edge insight from our partners

Events & webinars

Explore our programme of live & on-demand content